Nadofaragene firadenovec is under clinical development by FKD Therapies and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Nadofaragene firadenovec’s likelihood of approval (LoA) and phase transition for Malignant Pleural Mesothelioma took place on 19 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Nadofaragene firadenovec Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Nadofaragene firadenovec overview
Nadofaragene firadenovec (Adstiladrin) is a non-replicating adenoviral vector-based gene therapy. It is formulated as suspension for intravesical instillation. Adstiladrin is indicated for the treatment of adult patients with high-risk Bacillus CalmetteGuérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
FKD Therapies overview
FKD Therapies, is a gene-based medicine developer. The company is headquartered in Finland.
Quick View Nadofaragene firadenovec LOA Data
|Highest Development Stage|